SCOPUS 정보 검색 플랫폼

Journal of Thoracic Oncology

Volumn 6, Issue 6, 2011, Pages 1142-1143

Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease

(5) Dallas, Jennifer L a Jantz, Michael A b Lightsey, Judith L c Sonntag, Christopher d Kaye, Frederic J a,c

a Division of Hematology and Oncology (United States)

b Department of Medicine (United States)

c UNIVERSITY OF FLORIDA (United States)

d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; DOXYCYCLINE; ERLOTINIB; PREDNISONE;

ADULT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG RECHALLENGE; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; NOTE; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 79958137308 PISSN: 15560864 EISSN: 15561380 Source Type: Journal
DOI: 10.1097/JTO.0b013e318217b684 Document Type: Article

Times cited : (9)

References (5)

1
- 25144488564
- Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen
- DOI 10.1158/1078-0432.CCR-05-0790
- Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005;11:6414-6421. (Pubitemid 41338977)
- (2005) Clinical Cancer Research , vol.11 , Issue.18 , pp. 6414-6421
- Johnson, J.R.¹ Cohen, M.² Sridhara, R.³ Chen, Y.-F.⁴ Williams, G.M.⁵ Duan, J.⁶ Gobburu, J.⁷ Booth, B.⁸ Benson, K.⁹ Leighton, J.¹⁰ Hsieh, L.S.¹¹ Chidambaram, N.¹² Zimmerman, P.¹³ Pazdur, R.¹⁴

2
- 77954394701
- Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia
- Chang SC, Chang CY, Chen CY, et al. Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. J Thorac Oncol 2010;5:1105-1106.
- (2010) J Thorac Oncol , vol.5 , pp. 1105-1106
- Chang, S.C.¹ Chang, C.Y.² Chen, C.Y.³

3
- 75749127852
- Successful rechallenge with erlotinib in a patient with EGFR mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease
- Fukui T, Otani S, Hataishi R, et al. Successful rechallenge with erlotinib in a patient with EGFR mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemother Pharmacol 2010;65:803-806.
- (2010) Cancer Chemother Pharmacol , vol.65 , pp. 803-806
- Fukui, T.¹ Otani, S.² Hataishi, R.³

4
- 33745006872
- Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
- DOI 10.1200/JCO.2005.04.9866
- Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-2556. (Pubitemid 46630633)
- (2006) Journal of Clinical Oncology , vol.24 , Issue.16 , pp. 2549-2556
- Ando, M.¹ Okamoto, I.² Yamamoto, N.³ Takeda, K.⁴ Tamura, K.⁵ Seto, T.⁶ Ariyoshi, Y.⁷ Fukuoka, M.⁸

5
- 0242353929
- Doxycycline Is Anti-Inflammatory and Inhibits Staphylococcal Exotoxin-Induced Cytokines and Chemokines
- DOI 10.1128/AAC.47.11.3630-3633.2003
- Krakauer T, Buckley M. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother 2003;47:3630-3633. (Pubitemid 37345735)
- (2003) Antimicrobial Agents and Chemotherapy , vol.47 , Issue.11 , pp. 3630-3633
- Krakauer, T.¹ Buckley, M.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.